Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major cause of blood infections.

Janssen’s Roz Bekker, VP Commercial Strategy for Infectious Diseases & Vaccines at Janssen EMEA, looks at how COVID-19 has reinforced the value of connecting with people, and how healthcare ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

Dolores Catania has provided an update on the next season of The Real Housewives of New Jersey three months after the show ...

Just days after rubbing shoulders with Taylor Swift and Travis Kelce, American tennis star Frances Tiafoe’s bank account took ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

The risk of death is extremely low, with only nine deaths identified as being linked to the Johnson & Johnson/Janssen COVID-19 vaccine. As for people with epilepsy, there is currently no evidence that ...